Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Nov
02
Today In Oncology
Novel Strategy May Improve Outcomes in Patients With Treatment Resistant DLBCL
CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL
Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy
Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL
Shortening FDA Mandated CAR T Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo